JP2024016024A5 - - Google Patents

Download PDF

Info

Publication number
JP2024016024A5
JP2024016024A5 JP2023172391A JP2023172391A JP2024016024A5 JP 2024016024 A5 JP2024016024 A5 JP 2024016024A5 JP 2023172391 A JP2023172391 A JP 2023172391A JP 2023172391 A JP2023172391 A JP 2023172391A JP 2024016024 A5 JP2024016024 A5 JP 2024016024A5
Authority
JP
Japan
Prior art keywords
chain variable
variable region
light chain
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023172391A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024016024A (ja
JP7827951B2 (ja
Filing date
Publication date
Priority claimed from PCT/CN2021/083194 external-priority patent/WO2021190622A1/en
Application filed filed Critical
Publication of JP2024016024A publication Critical patent/JP2024016024A/ja
Publication of JP2024016024A5 publication Critical patent/JP2024016024A5/ja
Application granted granted Critical
Publication of JP7827951B2 publication Critical patent/JP7827951B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023172391A 2020-03-27 2023-10-03 抗体結合Siglec15及びその使用 Active JP7827951B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063000566P 2020-03-27 2020-03-27
US63/000,566 2020-03-27
PCT/CN2021/083194 WO2021190622A1 (en) 2020-03-27 2021-03-26 Antibodies binding siglec15 and uses thereof
JP2022547787A JP7364315B2 (ja) 2020-03-27 2021-03-26 抗体結合Siglec15及びその使用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022547787A Division JP7364315B2 (ja) 2020-03-27 2021-03-26 抗体結合Siglec15及びその使用

Publications (3)

Publication Number Publication Date
JP2024016024A JP2024016024A (ja) 2024-02-06
JP2024016024A5 true JP2024016024A5 (cg-RX-API-DMAC7.html) 2024-04-04
JP7827951B2 JP7827951B2 (ja) 2026-03-11

Family

ID=77891322

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022547787A Active JP7364315B2 (ja) 2020-03-27 2021-03-26 抗体結合Siglec15及びその使用
JP2023172391A Active JP7827951B2 (ja) 2020-03-27 2023-10-03 抗体結合Siglec15及びその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022547787A Active JP7364315B2 (ja) 2020-03-27 2021-03-26 抗体結合Siglec15及びその使用

Country Status (12)

Country Link
US (2) US11739147B2 (cg-RX-API-DMAC7.html)
EP (1) EP4126938A4 (cg-RX-API-DMAC7.html)
JP (2) JP7364315B2 (cg-RX-API-DMAC7.html)
KR (1) KR102651263B1 (cg-RX-API-DMAC7.html)
CN (1) CN115348970B (cg-RX-API-DMAC7.html)
AU (2) AU2021240769B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022019129A2 (cg-RX-API-DMAC7.html)
IL (1) IL296736B2 (cg-RX-API-DMAC7.html)
MX (1) MX2022011951A (cg-RX-API-DMAC7.html)
PH (1) PH12022552520A1 (cg-RX-API-DMAC7.html)
SA (1) SA522440646B1 (cg-RX-API-DMAC7.html)
WO (1) WO2021190622A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022011951A (es) * 2020-03-27 2023-03-06 Biosion Inc Anticuerpos de la lectina 15 similar a la inmunoglobulina que se une a acido sialico (siglec15) y usos de los mismos.
CN118159286A (zh) * 2021-11-25 2024-06-07 正大天晴药业集团股份有限公司 抗Siglec-15抗体及其应用
CN114134183B (zh) * 2021-12-24 2022-12-06 广东南模生物科技有限公司 一种siglec15基因人源化动物模型的构建方法及应用
CN114807052A (zh) * 2022-06-07 2022-07-29 江苏亲科生物研究中心有限公司 Siglec15单克隆抗体及其制备方法和用途
CN119403838A (zh) * 2022-06-13 2025-02-07 上海生物制品研究所有限责任公司 抗siglec15抗体及其用途
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2025247334A1 (en) * 2024-05-30 2025-12-04 Biosion Inc. Recombinant fusion protein targeting siglec15 and gm-csfr

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4604184B2 (ja) * 2005-07-12 2010-12-22 独立行政法人産業技術総合研究所 新規糖鎖認識蛋白質及びその遺伝子
US8168181B2 (en) * 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
CA2813314A1 (en) * 2010-10-05 2012-04-12 Daiichi Sankyo Company, Limited Antibody targeting osteoclast-related protein siglec-15
EP2753356B1 (en) 2011-09-09 2021-12-22 Medimmune Limited Anti-siglec-15 antibodies and uses thereof
JPWO2013147212A1 (ja) * 2012-03-30 2015-12-14 第一三共株式会社 新規抗Siglec−15抗体
AU2013293062A1 (en) * 2012-07-19 2014-07-24 Alethia Biotherapeutics Inc. Anti-Siglec-15 antibodies
US20170129956A1 (en) * 2014-06-18 2017-05-11 Daiichi Sankyo Company, Limited Anti-siglec-15 antibodies for use in treatment of osteogenesis imperfecta
KR102810368B1 (ko) 2015-11-10 2025-05-19 예일 유니버시티 자가면역 질환 및 암을 치료하기 위한 조성물 및 방법
KR102644544B1 (ko) * 2016-09-21 2024-03-11 넥스트큐어 인코포레이티드 Siglec-15를 위한 항체 및 이의 사용 방법
CN108250296B (zh) * 2018-01-17 2020-07-07 长春金赛药业有限责任公司 全人源抗人pd-l1单克隆抗体及其应用
CN112638947B (zh) * 2018-08-30 2022-09-30 上海斯丹赛生物技术有限公司 用于治疗实体瘤的嵌合抗原受体细胞
US11323026B2 (en) 2019-09-06 2022-05-03 Intel Corporation Hybrid digital linear and switched capacitor voltage regulator
MX2022011951A (es) * 2020-03-27 2023-03-06 Biosion Inc Anticuerpos de la lectina 15 similar a la inmunoglobulina que se une a acido sialico (siglec15) y usos de los mismos.
US20250361297A1 (en) * 2024-03-12 2025-11-27 Adaptam Therapeutics, S.L. Anti- siglec-15 binding molecules and methods of use

Similar Documents

Publication Publication Date Title
JP2023509196A5 (cg-RX-API-DMAC7.html)
JP2023518153A5 (cg-RX-API-DMAC7.html)
JP2023543031A5 (cg-RX-API-DMAC7.html)
RU2019116624A (ru) Новые анти_cd137 антитела и их применение
JP2020501531A5 (cg-RX-API-DMAC7.html)
JP2013502913A5 (cg-RX-API-DMAC7.html)
JP2014158469A5 (cg-RX-API-DMAC7.html)
JP2010504755A5 (cg-RX-API-DMAC7.html)
HRP20120701T1 (hr) Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1
CA2523449A1 (en) Recombinant antibodies and fragments which recognize n glycolil gm3 ganglioside and its use in diagnosis and treatment of tumours
JP2023540526A5 (cg-RX-API-DMAC7.html)
US20250034273A1 (en) Composition of multispecific antibodies targeting cadherin-17-expressing tumors and method of making and using thereof
JP2023529842A5 (cg-RX-API-DMAC7.html)
JP2024541680A5 (cg-RX-API-DMAC7.html)
JP2022553922A5 (cg-RX-API-DMAC7.html)
JP2023536461A5 (cg-RX-API-DMAC7.html)
JP2023517794A5 (cg-RX-API-DMAC7.html)
JP2022532991A5 (cg-RX-API-DMAC7.html)
JP2020533965A5 (cg-RX-API-DMAC7.html)
JP2022521305A (ja) 抗pd-l1抗体及びその使用
JP2023549316A5 (cg-RX-API-DMAC7.html)
JP2024020436A5 (cg-RX-API-DMAC7.html)
JP2023517754A5 (cg-RX-API-DMAC7.html)
JP2024517953A5 (cg-RX-API-DMAC7.html)
JP2025130076A5 (cg-RX-API-DMAC7.html)